Respiratory rate is the earliest and most sensitive indicator of patient deterioration, yet it is often poorly monitored. This innovative device can support hospitals to improve the detection of, and response to, clinical deterioration in patients with acute illness.
Up to six trusts will be selected to take part in the initial set-up phase for the pilot, with up to four being selected to go through to the full implementation phase, receiving a free six month supply of RespiraSense.
Myles Murray, inventor of RespiraSense said: “I’m excited to work with UCLPartners and trusts across the geography to improve monitoring of respiratory rate. By identifying deteriorating patients sooner, we hope that trusts will be able to improve the quality of care they provide for patients, and enable us to further evaluate the effectiveness of RespiraSense in a variety of real world settings.”
John Illingworth, Head of Patient Safety at UCLPartners said: “Improving the identification and management of patient deterioration is a local and national priority for the NHS, and an area UCLPartners has focused on for a number of years. By embracing new innovations like RespiraSense, we can continue to support hospitals across our geography to improve the quality and safety of care for acutely ill patients.”